Company Overview - Cullinan Therapeutics, Inc. (NASDAQ: CGEM) is a biopharmaceutical company that employs a modality-agnostic approach to drug development, targeting biological mechanisms in oncology and autoimmune conditions [1] Business Strategy - The company selects the most effective modality for each therapeutic target, indicating a flexible strategy that adapts to various treatment needs [1] Partnerships - Cullinan Therapeutics engages in partnerships to enhance its drug development capabilities, which may provide additional resources and expertise [1]